CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for DRI Healthcare Trust is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

DRI Healthcare Trust
1 First Canadian Place
Suite 7250, 100 King Street West
Phone: (416) 863-1865p:416 863-1865 Toronto, ON  M5X 1B1  Canada Ticker: DHT.UNDHT.UN
Business Summary
DRI Healthcare Trust is a Canada-based company engaged in providing financing to advance innovation in the life sciences industry. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It acquires approximately 70 royalties on 45-plus drugs, including Eylea, Spinraza, Zytiga, Remicade, Keytruda, Stelara, and Xenpozyme. Its portfolio includes Empaveli, Eylea, Natpara, Omidria, Rydapt, Simponi, Syfovre, Vonjo, Zejula and Zytiga. Its therapeutic areas include influenza, endocrinology, ophthalmology, dermatology, oncology, neurology, autoimmune diseases, heme-onc, lysosomal storage disorder, respiratory diseases, oncology and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; Novartis; Biogen; CTI Biopharma; Roche, Novartis, Johnson & Johnson, Sanofi S.A., and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
6794 Patent owners and lessors
2834 Pharmaceutical preparations

Business Names
Business Name
3IJ0
DHT.UN

General Information
Outstanding Shares: 56,269,049 (As of 9/30/2024)
Stock Exchange: TSE


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, February 22, 2025